Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NASDAQ | Common Stock
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe.
The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD).
The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.
It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | -0.24 Increased by +31.43% | -0.25 Increased by +4.00% |
| Feb 26, 24 | -0.17 Decreased by -13.33% | -0.15 Decreased by -13.33% |
| Nov 7, 23 | -0.17 Increased by +19.05% | -0.21 Increased by +19.05% |
| Aug 7, 23 | -0.28 Decreased by -211.11% | -0.21 Decreased by -33.33% |
| May 8, 23 | -0.35 Decreased by -59.09% | -0.26 Decreased by -34.62% |
| Feb 27, 23 | -0.15 Increased by +65.12% | -0.17 Increased by +11.76% |
| Nov 7, 22 | -0.21 Increased by +56.25% | -0.18 Decreased by -16.67% |
| Aug 4, 22 | -0.09 Increased by +88.75% | 0.11 Decreased by -181.82% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 15.69 M Increased by +26.04% | -8.95 M Decreased by -100.98% | Decreased by -57.03% Decreased by -100.77% |
| Jun 30, 23 | 13.75 M Increased by +24.43% | -15.64 M Decreased by -91.00% | Decreased by -113.79% Decreased by -53.51% |
| Mar 31, 23 | 10.42 M Decreased by -21.06% | -22.09 M Increased by +14.87% | Decreased by -212.04% Decreased by -7.84% |
| Dec 31, 22 | 14.65 M Decreased by -1.98% | -14.26 M Increased by +55.49% | Decreased by -97.33% Increased by +54.59% |
| Sep 30, 22 | 12.45 M Decreased by -5.63% | 916.63 M Increased by +2.70 K% | Increased by +7.36 K% Increased by +2.85 K% |
| Jun 30, 22 | 11.05 M Decreased by -14.43% | -8.19 M Increased by +84.37% | Decreased by -74.13% Increased by +81.73% |
| Mar 31, 22 | 13.20 M Decreased by -7.44% | -25.95 M Increased by +67.44% | Decreased by -196.62% Increased by +64.82% |
| Dec 31, 21 | 14.95 M Decreased by -20.21% | -32.03 M Increased by +45.18% | Decreased by -214.35% Increased by +31.29% |